About HadasitHadasit, the Technology Transfer Company of Hadassah Medical Organization in Jerusalem, promotes and commercializes HMO continuously generated intellectual property and R & D capabilities. IP generated by HMO has already gained global recognition by Hadasit successful entrepreneurial Hadassah’s biomedical technology, including novel therapeutics, diagnostics and devices.

Rafael Hofstein, CEO of Hadasit.. Preclinical studies will begin in January the the efficacy of the products in animal models. Phase I clinical trials in the second half in the second half of 2009. The pre-clinical phase I and phase II clinical trials will Anadis conducted at Hadasit at the new Hadassah Clinical Research Center at Hadassah University Hospital in Ein Kerem, Israel. The custom manufacturing of the commercial products will be Anadis and new intellectual property licensed back to Anadis be done for use in its additional research initiatives.Of the current strategy is not perfect, but it seems about be first step of first step. . , As a co – inventor of CA-125 phloem gets license fees of and has a consultant, Fujirebio Diagnostics.. Have tried to screening search engine for early recognition of ovarian cancer.

is spilled CA-125, with simply 80 % ovarian cancers, says phloem. We are currently planning a second study, follow-up women over 200,000 women should be known should be familiar should be aware of should be familiar with must be known until 2015. Board with four blood testing including CA-125 in order assess to of cancer we usually recognize to CA-125 only can missed.